NellOne Therapeutics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$242K
- Investors
-
13
NellOne Therapeutics General Information
Description
Developer of regenerative medicines designed to heal tissue after acute injury. The company's medicines uses a protein that triggers multiple processes for tissue growth and maturation during development and after injuries, enabling patients to relieve suffering and restore lives by returning damaged soft and hard tissue to its pre-injury state.
Contact Information
Website
www.nell-one.comCorporate Office
- 11020 Solway School Road
- Suite 101
- Knoxville, TN 37931
- United States
Corporate Office
- 11020 Solway School Road
- Suite 101
- Knoxville, TN 37931
- United States
NellOne Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 01-Apr-2021 | $242K | Completed | Generating Revenue | ||
| 3. Angel (individual) | 01-Jan-2013 | Completed | Generating Revenue | |||
| 2. Grant | 03-Nov-2010 | $1.5M | Completed | Generating Revenue | ||
| 1. Seed Round | 04-Jun-2008 | $1.5M | $1.5M | Completed | Generating Revenue |
NellOne Therapeutics Comparisons
Industry
Financing
Details
NellOne Therapeutics Competitors (1)
One of NellOne Therapeutics’s competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
NellOne Therapeutics Patents
NellOne Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220001084-A1 | Composite stint apparatus and fabrication method | Inactive | 02-Jul-2020 | ||
| EP-4132956-A2 | Methods and compositions for treating tissue damage resulting from viral infections | Pending | 10-Apr-2020 | ||
| EP-4132956-A4 | Methods and compositions for treating tissue damage resulting from viral infections | Pending | 10-Apr-2020 | ||
| US-20230116082-A1 | Methods and compositions for treating tissue damage resulting from viral infections | Inactive | 10-Apr-2020 | ||
| WO-2021206833-A2 | Methods and compositions for treating tissue damage resulting from viral infections | Inactive | 10-Apr-2020 | A61K38/1808 |
NellOne Therapeutics Signals
NellOne Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| US National Science Foundation | Accelerator/Incubator | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority |
NellOne Therapeutics FAQs
-
When was NellOne Therapeutics founded?
NellOne Therapeutics was founded in 2007.
-
Where is NellOne Therapeutics headquartered?
NellOne Therapeutics is headquartered in Knoxville, TN.
-
What is the size of NellOne Therapeutics?
NellOne Therapeutics has 6 total employees.
-
What industry is NellOne Therapeutics in?
NellOne Therapeutics’s primary industry is Drug Discovery.
-
Is NellOne Therapeutics a private or public company?
NellOne Therapeutics is a Private company.
-
What is NellOne Therapeutics’s current revenue?
The current revenue for NellOne Therapeutics is .
-
How much funding has NellOne Therapeutics raised over time?
NellOne Therapeutics has raised $1.5M.
-
Who are NellOne Therapeutics’s investors?
US National Science Foundation, , , , and are 5 of 13 investors who have invested in NellOne Therapeutics.
-
Who are NellOne Therapeutics’s competitors?
Bristol-Myers Squibb is a competitor of NellOne Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process